Loading...
Loading...
EBS| Name | Value |
|---|---|
| Revenues | 300.4M |
| Cost of Revenue | 161.0M |
| Gross Profit | 139.4M |
| Operating Expense | 99.6M |
| Operating I/L | 39.8M |
| Other Income/Expense | -27.7M |
| Interest Income | 0.0M |
| Pretax | 12.1M |
| Income Tax Expense | 3.1M |
| Net Income/Loss | 9.0M |
Emergent BioSolutions Inc. is a life sciences company specializing in preparedness and response solutions for public health threats in the United States. The company's products include vaccines for anthrax and smallpox, treatments for botulism and opioid overdose, as well as vaccines for typhoid fever, cholera, and influenza. Additionally, it is developing a range of products such as sustained release injections for opioid use disorder, universal influenza vaccines, and antidotes for cyanide poisoning. Emergent BioSolutions also offers contract development and manufacturing services for drug substance and product manufacturing, packaging, and technology transfer.
